false000183136300018313632024-06-102024-06-10

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 10, 2024

 

 

Terns Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-39926

98-1448275

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

1065 East Hillsdale Blvd.

Suite 100

 

Foster City, California

 

94404

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 525-5535

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

TERN

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 10, 2024, Terns Pharmaceuticals, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 25, 2024. Only stockholders of record as of the close of business on April 18, 2024, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 64,674,780 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows:

Proposal 1. The election of two Class III directors to hold office until the 2027 annual meeting of stockholders or until their respective successor is elected:

 

 

 

Nominee

Votes For

Votes Withheld

Broker Non-Votes

Jeffrey Kindler

45,958,352

6,735,358

5,131,121

Amy Burroughs

52,570,019

123,691

5,131,121

Proposal 2. The ratification of the selection, by the audit committee of the board of directors, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024:

 

 

 

Votes For

Votes Against

Abstentions

57,570,954

23,950

229,927

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

TERNS PHARMACEUTICALS, INC.

 

 

 

 

Date:

June 12, 2024

By:

/s/ Bryan Yoon

 

 

 

Bryan Yoon
Chief Operating Officer & General Counsel

 

v3.24.1.1.u2
Document And Entity Information
Jun. 10, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 10, 2024
Entity Registrant Name Terns Pharmaceuticals, Inc.
Entity Central Index Key 0001831363
Entity Emerging Growth Company true
Entity File Number 001-39926
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 98-1448275
Entity Address, Address Line One 1065 East Hillsdale Blvd.
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Foster City
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94404
City Area Code (650)
Local Phone Number 525-5535
Entity Information, Former Legal or Registered Name N/A
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol TERN
Security Exchange Name NASDAQ
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Terns Pharmaceuticals Charts.
Terns Pharmaceuticals (NASDAQ:TERN)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Terns Pharmaceuticals Charts.